close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Surface Oncology, Inc. - Common Stock (NQ:SURF)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Surface Oncology, Inc. - Common Stock

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting 
From Surface Oncology, Inc.
Via GlobeNewswire
SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
From Kahn Swick & Foti, LLC
Via Business Wire
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
From Surface Oncology, Inc.
Via GlobeNewswire
SURFACE ONCOLOGY INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
From Kahn Swick & Foti, LLC
Via Business Wire
SURF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surface Oncology, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Coherus to Acquire Surface Oncology
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models – 
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
From Surface Oncology, Inc.
Via GlobeNewswire
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform 
From Vaccinex, Inc.
Via GlobeNewswire
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
Data further support SRF388 and SRF114 clinical development programs 
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
From Surface Oncology, Inc.
Via GlobeNewswire
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
From Surface Oncology, Inc.
Via GlobeNewswire
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today